US20220313690A1 - Synergistic effect of eyp001 and ifn for the treatment of hbv infection - Google Patents

Synergistic effect of eyp001 and ifn for the treatment of hbv infection Download PDF

Info

Publication number
US20220313690A1
US20220313690A1 US17/627,708 US202017627708A US2022313690A1 US 20220313690 A1 US20220313690 A1 US 20220313690A1 US 202017627708 A US202017627708 A US 202017627708A US 2022313690 A1 US2022313690 A1 US 2022313690A1
Authority
US
United States
Prior art keywords
eyp001
ifn
administered
hbv
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/627,708
Other languages
English (en)
Inventor
Jacky Vonderscher
Elise Roy
Raphaël Darteil
Pietro Scalfaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enyo Pharma SA
Original Assignee
Enyo Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enyo Pharma SA filed Critical Enyo Pharma SA
Assigned to ENYO PHARMA reassignment ENYO PHARMA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCALFARO, PIETRO, Darteil, Raphaël , ROY, Elise, VONDERSCHER, JACKY
Publication of US20220313690A1 publication Critical patent/US20220313690A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a method for treating Hepatitis B infection.
  • Hepatitis B remains a major worldwide public health problem with over 350 million of chronically-infected people despite extensive vaccination programs. Chronic hepatitis B evolves towards life threatening complications including liver cirrhosis and cancer. Current therapeutic regimens are long term treatments (e.g., polymerase inhibitors, life long; pegylated interferons up to one year) and fail to cure HBV as they do not target the virus reservoir. HBV functional cure remains a major unmet medical need.
  • CHB infection chronic hepatitis B
  • Seven drugs are currently available for treatment of CHB infection —conventional interferon (IFN), pegylated interferon and direct antiviral agents.
  • IFN conventional interferon
  • pegylated interferon drugs that are currently available for treatment of CHB infection —conventional interferon (IFN), pegylated interferon and direct antiviral agents.
  • the direct antivirals nucleos/tide analogues
  • L-nucleosides laamivudine, telbivudine and emtricitabine
  • deoxyguanosine analogs entecavir
  • nucleoside phosphonates adefovir and tenofovir
  • cccDNA reside in the cell nucleus as additional minichromosomes that are transcribed into viral mRNAs and transmitted to daughter cells when hepatocytes divide.
  • Current direct antivirals have no or very little effect on the HBV cccDNA reservoir and the expression of the viral genes.
  • the currently available treatments are suboptimal and may be associated with severe side effects.
  • EYP001 is a synthetic non-steroidal, non-bile acid FXR agonist with a good tolerability profile.
  • EYP001 is an orally bioavailable small molecule currently evaluated in phase Ib in patients with chronic hepatitis B. Contrary to lifelong standards of care that target essentially virus replication, EYP001 is targeting the cccDNA (‘virus reservoir’), therefore aiming for HBV real cure.
  • Erken et al 2018, Journal of Hepatology, 68, Suppl 1, S488-S489) discloses that EYP001 reduces HBV viral load in chronic hepatitis B patients.
  • EYP001 has a synergistic effect with interferon for the treatment of hepatitis B, especially on pre-genomic viral RNA, a marker of viral replication, and on HBcrAg, a core related antigen which is a serum marker of chronic hepatitis B. Accordingly, EYP001 and IFN have a synergistic effect on the reduction of cccDNA transcription. These effects were observed after only 4 weeks of treatment which is a very short period of time, whereas neither EYP001 and nor IFN when used alone do not show a significant effect at the same dose and after the same period of time. In addition, surprisingly, the synergistic effect is at least two-fold stronger when EYP001 is administered once a day in comparison to an administration twice a day with the same daily dosing.
  • the present invention relates to the synergistic combination of EYP001 and IFN for use in the treatment of hepatitis B infection, especially chronic hepatitis B.
  • the present invention relates to EYP001 or a pharmaceutic composition comprising it for use in combination with interferon alpha (IFN- ⁇ ) or a pegylated form thereof for the treatment of hepatitis B virus infection, especially chronic hepatitis B, wherein EYP001 and IFN- ⁇ are used so as to obtain a synergistic effect for decreasing the HBV replication.
  • IFN- ⁇ interferon alpha
  • EYP001 or a pharmaceutical composition comprising it for the manufacture of a drug for the treatment of hepatitis B virus infection, especially chronic hepatitis B, in combination with interferon alpha (IFN- ⁇ ) or a pegylated form thereof, wherein EYP001 and IFN- ⁇ are used so as to obtain a synergistic effect for decreasing the HBV replication.
  • IFN- ⁇ interferon alpha
  • EYP001 is to be administered at a dose in the range from 50 to 800 mg per day. More particularly, EYP001 is to be administered at a dose in the range from 100 to 600 mg, preferably from 200 to 400 mg per day. Optionally, EYP001 is to be administered at a sub-therapeutic amount.
  • EYP001 is to be administered once a day. In another aspect, EYP001 is to be administered twice a day.
  • the IFN- ⁇ is IFN- ⁇ 2a, IFN- ⁇ 2b or a pegylated form thereof.
  • IFN- ⁇ or a pegylated form thereof is to be administered by subcutaneous route once a week.
  • IFN- ⁇ or a pegylated form thereof can be administered at a sub-therapeutic amount.
  • both EYP001 and IFN- ⁇ or a pegylated form thereof are to be administered at sub-therapeutic amounts.
  • EYP001 and IFN- ⁇ or a pegylated form thereof are to be administered during a period of time from 5 6, 7 or 8 weeks to 52 weeks.
  • EYP001 and IFN- ⁇ or a pegylated form thereof are to be used in combination with at least one additional active ingredient.
  • the at least one additional active ingredient is a polymerase inhibitor selected from the group consisting of L-nucleosides, deoxyguanosine analogs and nucleoside phosphonates.
  • the at least one additional active ingredient is selected from the group consisting of lamivudine, telbivudine, emtricitabine, entecavir, adefovir and tenofovir.
  • FIG. 1 HBV pgRNA (log 10 copies/mL) changes from baseline after a 4 week anti-HBV treatment course of FXR agonist EYP001a or placebo in combination with interferon in chronically infected previously untreated HBV patients.
  • PBO placebo.
  • peg-IFN pegylated interferon alpha2a.
  • 150 BID 150 mg twice daily.
  • 300 QD 300 mg once daily.
  • FIG. 2 HBcrAg (log 10 IU/mL) changes from baseline after a 4 week anti-HBV treatment course of FXR agonist EYP001a or placebo in combination with interferon in chronically infected previously untreated HBV patients.
  • PBO placebo.
  • peg-IFN pegylated interferon alpha2a.
  • HBcrAg hepatitis B core-related antigen. Black columns are changes at end of treatment Day 29. Grey columns are changes one week after end of treatment at Day 35.
  • EYP001 is an FXR agonist disclosed in CAS number 1192171-69-9 and having the following formula:
  • EYP001 is intended to refer to this compound and any pharmaceutically acceptable salt thereof.
  • EYP001 surprisingly leads to a synergistic effect on chronic hepatitis B after only 4 weeks of treatment, a very short period whereas none of EYP001 or IFN- ⁇ alone shows any significant effect.
  • the effect has been observed on the pre-genomic RNA (HBV pgRNA) and on the hepatitis B core related antigen (HBcrAg). Therefore, a therapeutic benefit can be obtained for the patient by using the synergistic combination of EYP001 with IFN- ⁇ .
  • treatment refers to any act intended to ameliorate the health status of patients such as therapy, prevention, prophylaxis and retardation of a disease.
  • such terms refer to the amelioration or eradication of the disease, or symptoms associated with it.
  • this term refers to minimizing the spread or worsening of the disease, resulting from the administration of one or more therapeutic agents to a subject with such a disease.
  • treating means alleviating HBV infection, arresting disease development, and/or removing HBV by administering the composition.
  • HBV replication is decreased by at least 10 or 100 fold in comparison with the HBV replication in absence of More particularly, the treatment of hepatitis B infection, especially chronic hepatitis B, is shown by a decrease of HBV replication.
  • the HBV replication can be assessed by determining at least one of HBeAg levels, HBsAg levels, HBcrAg levels, pre-genomic RNA (HBV pgRNA) levels, pre-core RNA levels, relaxed circular DNA (HBV rcDNA) levels, HBV cccDNA levels or HBV DNA levels in the subject.
  • HBeAg levels HBeAg levels
  • HBsAg levels HBsAg levels
  • HBcrAg levels pre-genomic RNA
  • pre-core RNA levels pre-core RNA levels
  • HBV cccDNA levels relaxed circular DNA
  • HBV cccDNA levels relaxed circular DNA
  • HBeAg levels HBsAg levels, HBcrAg levels, pre-genomic RNA (HBV pgRNA) levels, pre-core RNA levels, relaxed circular DNA (HBV rcDNA) levels, HBV cccDNA levels and HBV DNA levels is decreased in comparison with the absence of treatment.
  • HBeAg levels HBsAg levels, HBcrAg levels, pre-genomic RNA (HBV pgRNA) levels, pre-core RNA levels, relaxed circular DNA (HBV rcDNA) levels, HBV cccDNA levels and HBV DNA levels is decreased in comparison with the absence of treatment.
  • HBeAg levels HBsAg levels
  • HBcrAg levels pre-genomic RNA
  • pre-core RNA levels pre-core RNA levels
  • HBV cccDNA levels relaxed circular DNA levels
  • HBV cccDNA levels HBV DNA levels
  • HBV replication is decreased by at least 10 or 100 fold in comparison with the HBV replication in absence of treatment.
  • the HBV replication can be assessed by determining the HBV DNA levels and this level is decreased by at least 10 or 100 fold in comparison with the HBV replication in absence of EYP001.
  • HBV cccDNA level is decreased by at least 10, 15, 20, 25, 30, 35, 40, 45 or 50% in comparison with the absence of treatment.
  • the terms “subject”, “individual” or “patient” are interchangeable and refer to a human, including adult, child, newborn and human at the prenatal stage.
  • the subject or patient suffers of hepatitis B infection, in particular a chronic hepatitis B.
  • Quantity is used interchangeably herein and may refer to an absolute quantification of a molecule.
  • the term “therapeutic effect” refers to an effect induced by an active ingredient, or a pharmaceutical composition according to the invention, capable to prevent or to delay the appearance or development of a disease or disorder, or to cure or to attenuate the effects of a disease or disorder.
  • the term “therapeutically effective amount” refers to a quantity of an active ingredient or of a pharmaceutical composition which prevents, removes or reduces the deleterious effects of the disease, particularly infectious disease. It is obvious that the quantity to be administered can be adapted by the man skilled in the art according to the subject to be treated, to the nature of the disease, etc. In particular, doses and regimen of administration may be function of the nature, of the stage and of the severity of the disease to be treated, as well as of the weight, the age and the global health of the subject to be treated, as well as of the judgment of the doctor.
  • sub-therapeutic amount refers to a dosage which is less than that dosage which would produce a therapeutic result in the subject if administered in the absence of the other agent.
  • “sub-therapeutic amount” or “sub-therapeutic dose” can refer to a dosage which is decreased by 25, 50, 70, 80 or 90% in comparison to the therapeutically effective amount, especially the conventional therapeutic dosage for the same indication and the same administration route when used alone.
  • the conventional therapeutic dosages are those acknowledged by the drug approvals agencies (e.g., FDA or EMEA).
  • excipient or pharmaceutically acceptable carrier refers to any ingredient except active ingredients that is present in a pharmaceutical composition. Its addition may be aimed to confer a particular consistency or other physical or gustative properties to the final product. An excipient or pharmaceutically acceptable carrier must be devoid of any interaction, in particular chemical, with the active ingredients.
  • pegylated form refers to a pegylated interferon.
  • HBV replication can be assessed by determining surface HBV antigen (HBsAg), HBeAg, HBV core related antigen (HBcrAg), HBV DNA, HBV pre-genomic RNA, HBV pre-core RNA and/or HBV cccDNA. More particularly, the effect is observed on the pre-genomic RNA (HBV pgRNA) and/or on the hepatitis B core related antigen (HBcrAg).
  • the present invention relates to the use of a combination of EYP001 and IFN for the treatment of hepatitis B virus infection, especially chronic hepatitis B. Indeed, this combination leads to a synergistic effect against HBV.
  • the present invention relates to
  • the IFN- ⁇ can be for instance IFN- ⁇ 1 or IFN- ⁇ 2, e.g., IFN- ⁇ 1a, IFN- ⁇ 1b, IFN- ⁇ 2a, IFN- ⁇ 2b, IFN- ⁇ 2c or consensus IFN- ⁇ .
  • IFN is IFN- ⁇ 2a, IFN- ⁇ 2b or a pegylated form thereof.
  • IFN- ⁇ is selected from the non-exhaustive list consisting of consensus IFN- ⁇ (e.g., INFERGEN®, Locteron®), IFN- ⁇ 1b (e.g., HAPGEN®), IFN- ⁇ 2a (Roferon-A®, MOR-22, Inter 2A, Inmutag, Inferon), a pegylated IFN- ⁇ 2a (e.g., PEGASYS®, YPEG-IFN ⁇ -2a, PEG-INTRON®, Pegaferon), IFN- ⁇ 2b (e.g., INTRON A®, Alfarona, Bioferon, Inter 2B, citpheron, Zavinex, Ganapar, etc. . . .
  • consensus IFN- ⁇ e.g., INFERGEN®, Locteron®
  • IFN- ⁇ 1b e.g., HAPGEN®
  • IFN- ⁇ 2a Rosferon-A®, MOR-22, Inter 2A, Inmuta
  • IFN is a pegylated IFN- ⁇ 2a (e.g., PEGASYS®) or a pegylated IFN- ⁇ 2b (Pegintron®).
  • the IFN ⁇ or a pegylated form thereof is administered by subcutaneous route once a week; for instance, at a dosage varying from 1 ⁇ g to 500 ⁇ g, preferably from 10 ⁇ g to 500 ⁇ g, still more preferably from 100 ⁇ g to 250 ⁇ g, such as 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 or 200 ⁇ g.
  • the IFN ⁇ or a pegylated form thereof can be administered at a sub-therapeutic amount.
  • EYP001 can be administered at a therapeutic amount effective once or twice a day; more specifically, at a daily dose from 50 to 800 mg per adult per day, preferably from 100 to 600 mg per adult per day; still more preferably from 150 to 400 mg per adult per day or from 200 to 400 mg per day and for instance about 300 mg per adult per day; preferably orally.
  • the combined therapy comprising EYP001 and IFN- ⁇ is effective for decreasing the replication of HBV.
  • EYP001 and IFN- ⁇ i.e., IFN- ⁇ 2a, IFN- ⁇ 2b or a pegylated form thereof
  • the inventors surprisingly observed a synergistic effect is at least twice stronger when EYP001 is administered once a day in comparison with an administration twice a day with the same daily dosing.
  • the inventors observed that, surprisingly, fewer pruritus occurs when EYP001 is administered once a day rather than twice a day. Therefore, in a particular aspect, EYP001 is administered once a day.
  • EYP001 is administered in the evening (e.g., 6 and 10 pm). In an alternative aspect, EYP001 is administered in the morning (e.g., between 6 and 10 am).
  • EYP001 is administered with or without food. Then, in a first aspect, EYP001 is administered during the meal, e.g., just before, simultaneously or just after the meal. In a second aspect, EYP001 is administered at least one hour or two hours before or after the meal.
  • the composition, dosage unit or dosage form contains 5, 10, 15, 25, 50, 75, 100, 200, 300, 400 and 500 mg of EYP001 for the symptomatic adjustment of the dosage to the patient to be treated.
  • a medicament typically contains from about 5 mg to about 500 mg of EYP001, preferably from 50 mg to about 500 mg of EYP001, from 50 mg to about 450 mg of EYP001, from 100 mg to about 400 mg of EYP001, or from 150 mg to about 300 mg of EYP001.
  • the dosage form can be a scored dosage form.
  • the daily dosage can be provided by administering several dosage forms.
  • the EYP001 may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form pharmaceutical compositions.
  • “Pharmaceutically” or “pharmaceutically acceptable” refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate.
  • a pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • compositions comprising EYP001 can be suitable for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, preferably for oral administration.
  • the EYP001 can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports.
  • Suitable unit administration forms comprise oral-route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms.
  • the oral dosage form is a capsule or a tablet.
  • the oral dosage form is a scored dosage form.
  • the dosage form can be scored into four pieces, three pieces or two pieces.
  • the treatment lasts from 2-4 months up to 24 months, for instance between 2 and 24 months or between 2 and 12 months, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 months.
  • the treatment lasts from 12 to 52 weeks, preferably from 45 to 52 weeks, for instance 48 weeks.
  • EYP001 and IFN- ⁇ or a pegylated form thereof can be used in combination with at least one additional active ingredient.
  • the additional active ingredient is an antiviral, more particularly an antiviral having an activity against HBV.
  • the at least one additional active ingredient is a polymerase inhibitor selected from the group consisting of L-nucleosides, deoxyguanosine analogs and nucleoside phosphonates.
  • the at least one additional active ingredient is selected from the group consisting of lamivudine, telbivudine, emtricitabine, entecavir, adefovir and tenofovir.
  • ETV entecavir
  • Patient characteristics were: mean age of 39.7 years (range: 19-63); 6 of 73 were HBeAg-positive; 70% treatment na ⁇ ve; mean baselines HBV DNA 4.2 ( ⁇ 1.5 SD) log 10 IU/mL, HBsAg 3.5 ( ⁇ 0.8 SD) log 10 IU/mL, and genotypes A (25), B (8), C (10), D (7) and E (4).
  • Detailed virology characteristics are summarized in Table 2 and 3. FXR engagement with all EYP001 doses led to decreases in C4 and increases in FGF19 (data not shown).
  • EYP001 decreases the mean HBsAg by ⁇ 0.1 log 10 IU/mL (p ⁇ 0.05).
  • early markers of HBV replication pgRNA and HBcrAg showed a synergistic decrease when EYP001 was combined with peg-IFN, but not with peg-IFN or EYP001 monotherapies (Table 1).
  • This effect lasted at day 35, i.e. 7 days after end of treatment (EoT, FIG. 1 and FIG. 2 ). A stronger synergistic effect is observed with QD in comparison to BID.
  • Mean SD Mean SD (a) ETV 7 ⁇ 0.3 2.0 0.67 0.03 0.6 0.91 (open-label 0.5 mg/day) EYP001a (1 ⁇ 7 0.5 1.2 0.33 ⁇ 0.3 1.1 0.45 100 mg/day) EYP001a (1 ⁇ 8 0.4 1.7 0.59 0.2 1.1 0.56 200 mg/day) EYP001a (1 ⁇ 8 0.2 1.4 0.65 0.02 0.1 0.50 400 mg/day) EYP001a (2 ⁇ 7 ⁇ 0.1 1.9 0.92 1.2 2.2 0.19 200 mg/day) EYP001a (1 ⁇ 8 ⁇ 1.7 1.9 0.04 * ⁇ 0.9 1.6 0.15 300 mg/day) + Peg-IFN EYP001a (2 ⁇ 8 ⁇ 0.9 1.8 0.19 ⁇ 0.2 0.2 0.06 150 mg/day) + Peg-IFN Placebo + 8 ⁇

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
US17/627,708 2019-07-18 2020-07-17 Synergistic effect of eyp001 and ifn for the treatment of hbv infection Pending US20220313690A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19186941.1 2019-07-18
EP19186941 2019-07-18
PCT/EP2020/070241 WO2021009333A1 (fr) 2019-07-18 2020-07-17 Effet synergique d'eyp001 et d'ifn pour le traitement d'une infection par le virus de l'hépatite b

Publications (1)

Publication Number Publication Date
US20220313690A1 true US20220313690A1 (en) 2022-10-06

Family

ID=67437952

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/627,708 Pending US20220313690A1 (en) 2019-07-18 2020-07-17 Synergistic effect of eyp001 and ifn for the treatment of hbv infection

Country Status (12)

Country Link
US (1) US20220313690A1 (fr)
EP (1) EP3999069B1 (fr)
JP (1) JP7376679B2 (fr)
KR (1) KR102662826B1 (fr)
CN (1) CN114051411B (fr)
AU (1) AU2020314081A1 (fr)
CA (1) CA3140325C (fr)
ES (1) ES2968931T3 (fr)
IL (1) IL289069B2 (fr)
MX (1) MX2021016022A (fr)
PL (1) PL3999069T3 (fr)
WO (1) WO2021009333A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1238053C (zh) * 2002-12-02 2006-01-25 美德（江西）生物科技有限公司 含alfa－干扰素，拉米夫定和阿地福韦酯的药包
EP1886685A1 (fr) * 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
CZ2007494A3 (cs) 2007-07-20 2008-11-12 Ceské vysoké ucení technické v Praze Optický clen pro rentgenovou mikroskopii
RU2013148779A (ru) * 2011-04-01 2015-05-10 Новартис Аг Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
CN105764569B (zh) * 2013-09-11 2019-09-13 国家医疗保健研究所 治疗乙型肝炎病毒感染的方法和药物组合物
US20220265817A1 (en) * 2017-05-31 2022-08-25 Arbutus Biopharma Corporation Therapeutic compositions and methods for treating hepatitis b
CN107441098A (zh) * 2017-06-28 2017-12-08 河南大学 Fxr拮抗剂在在制备抗hbv药物中的应用

Also Published As

Publication number Publication date
CN114051411A (zh) 2022-02-15
EP3999069B1 (fr) 2023-10-11
CA3140325A1 (fr) 2021-01-21
EP3999069C0 (fr) 2023-10-11
KR20220035437A (ko) 2022-03-22
ES2968931T3 (es) 2024-05-14
EP3999069A1 (fr) 2022-05-25
PL3999069T3 (pl) 2024-03-25
MX2021016022A (es) 2022-02-03
IL289069B (en) 2022-11-01
IL289069B2 (en) 2023-03-01
CN114051411B (zh) 2022-10-28
KR102662826B1 (ko) 2024-05-03
WO2021009333A1 (fr) 2021-01-21
JP2022540697A (ja) 2022-09-16
IL289069A (en) 2022-02-01
CA3140325C (fr) 2022-07-19
JP7376679B2 (ja) 2023-11-08
AU2020314081A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
US20200276198A1 (en) Combination therapy of an hbv capsid assembly inhibitor and an interferon
JP2024026214A5 (fr)
JP5869469B2 (ja) 鉄が病因に関与する肝臓疾患の処置
WO2018087345A1 (fr) Polythérapie comprenant un inhibiteur d'un antigène de hbsag, un analogue nucléosidique ou nucléotidique et un interféron
US20220249469A1 (en) Improved treatment using eyp001
US20220313690A1 (en) Synergistic effect of eyp001 and ifn for the treatment of hbv infection
US20240100125A1 (en) Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
EA046230B1 (ru) Синергическое действие eyp001 и ifn при лечении инфекции hbv
WO2021170741A1 (fr) Traitement du vhb
Korkmaz et al. Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients
Dienstag et al. FRESH FROM THE PIPELINE

Legal Events

Date Code Title Description
AS Assignment

Owner name: ENYO PHARMA, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VONDERSCHER, JACKY;ROY, ELISE;DARTEIL, RAPHAEL;AND OTHERS;SIGNING DATES FROM 20220315 TO 20220322;REEL/FRAME:059484/0455

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION